RT Journal Article
SR Electronic
T1 Molecular Feature-Based Classification of Retroperitoneal Liposarcoma: A Prospective Cohort Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.09.24311657
DO 10.1101/2024.08.09.24311657
A1 Xiao, Mengmeng
A1 Li, Xiangji
A1 Bu, Fanqin
A1 Ma, Shixiang
A1 Yang, Xiaohan
A1 Chen, Jun
A1 Zhao, Yu
A1 Cananzi, Ferdinando
A1 Luo, Chenghua
A1 Min, Li
YR 2024
UL http://medrxiv.org/content/early/2024/08/09/2024.08.09.24311657.abstract
AB Background Retroperitoneal liposarcoma (RPLS) is a critical malignant disease with various clinical outcomes. However, the molecular heterogeneity of RPLS was poorly elucidated, and few biomarkers were proposed to monitor its progression.Methods RNA sequencing was performed on a training cohort of 88 RPLS patients to identify dysregulated genes and pathways using clusterprofiler. The GSVA algorithm was utilized to assess signaling pathways levels in each sample, and unsupervised clustering was employed to distinguish RPLS subtypes. Differentially expressed genes (DEGs) between RPLS subtypes were identified to construct a simplified dichotomous clustering via nonnegative matrix factorization. The feasibility of this classification was validated in a separate validation cohort (n=241) using immunohistochemistry (IHC) from the Retroperitoneal SArcoma Registry (RESAR). The study is registered with ClinicalTrials.gov under number NCT03838718.Results Cell cycle, DNA damage & repair, and Metabolism were identified as the most aberrant biological processes in RPLS, enabling the division of RPLS patients into two distinct subtypes with unique molecular signatures, tumor microenvironment, clinical features and outcomes (overall survival, OS and disease-free survival, DFS). A simplified RPLS classification based on representative biomarkers (LEP and PTTG1) demonstrated high accuracy (AUC>0.99), with patients classified as LEP+ and PTTG1-showing lower aggressive pathological composition ratio and fewer surgery times, along with better OS (HR=0.41, P<0.001) and DFS (HR=0.60, P=0.005).Conclusions Our study provided an ever-largest gene expression landscape of RPLS and established an IHC-based molecular classification that was clinically relevant and cost-effective for guiding treatment decisions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Beijing Municipal Science and Technology Project (Z191100006619081), National Natural Science Foundation of China (82073390), and Young Elite Scientists Sponsorship Program (2023QNRC001). The study sponsors had no role in the design and preparation of this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Specimens of RPLS were obtained from Peking University International Hospital. The study protocol was approved by the Ethics Committee of Peking University International Hospital, Peking University Health Science Center (WA2020RW29) and conducted in accordance with Helsinki Declaration. All patients signed the informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData supporting the conclusions of this article are presented within the article and its supplementary files.RPLSRetroperitoneal liposarcomaDEGsDifferentially expressed genesIHCImmunohistochemistrySTSSoft tissue sarcomaOSOverall survivalDFSDisease-free survivalOMIXOpen archive for miscellaneous dataCNCBChina national center for bioinformationGSEAGene set enrichment analysisGOGene ontologyKEGGKyoto encyclopedia of gene and genomest-SNEt-distributed stochastic neighbor embeddingDBSCANDensity-based spatial clustering of applications with noiseNMFNonnegative matrix factorizationLRLogistic regressionSVMSupport vector machineRFRandom forestAUCArea under curve